Replies to post #14325 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

MNTA reports 3Q15 results—GAAP loss of $30.1M on soft Glatopa profit-sharing income of $8.7M:

http://finance.yahoo.com/news/momenta-pharmaceuticals-reports-third-quarter-130000831.html

At 9/30/15, MNTA had $395.6M of cash (including $20.7M of restricted cash), down slightly from $397.9M at 6/30/15 (#msg-116222279).

MNTA expects 4Q15 cash usage of $40-42M, excluding Glatopa profit-sharing income.